Código QR

Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China

Background: Maintenance therapy with the poly (ADP-ribose) polymerase inhibitors (PARPis) for platinum-sensitive recurrent ovarian carcinoma (OC) have proven to be effective compared with placebo. We aimed to evaluate the cost-effectiveness (CE) of maintenance fuzuloparib compared to routine surveil...

Descrición completa

Gardado en:
Principais autores: Jing Nie, Huina Wu, Lei Sun, Yanjiao Ding, Yepeng Luan, Jiyong Wu
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Pharmacology
Assuntos:
fuzuloparib
niraparib
olaparib
cost-effectiveness
maintenance treatment
ovarian cancer
Acceso en liña:https://www.frontiersin.org/articles/10.3389/fphar.2022.987337/full
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares